Andrea Mafficini

High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers.

Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.

High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.

Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.

Reporting tumor molecular heterogeneity in histopathological diagnosis.

Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components.

Impact of MIF gene promoter polymorphism on F508del cystic fibrosis patients.

Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium.

Next-generation sequencing for genetic testing of familial colorectal cancer syndromes.

A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.

New genomic landscapes and therapeutic targets for biliary tract cancers.

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.

Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.

Whole-genome landscape of pancreatic neuroendocrine tumours.

Fhit down-regulation is an early event in pancreatic carcinogenesis.

Splice variants as novel targets in pancreatic ductal adenocarcinoma.

A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients.

Non-coding regulatory variations: the dark matter of pancreatic cancer genomics.

Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma.

Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium.

Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.

Frequent fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression.

Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.

PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications.

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.

ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance.

Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.

Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.

Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis.

Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms.

Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.

Ultra-Mutation in Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment.